"Replicative stress" is one of the main factors underlying neoplasia from its early stages. Genes involved in DNA synthesis may therefore represent an underexplored source of potential prognostic markers for cancer. To this aim, we generated gene expression profiles from two independent cohorts (France, n = 206; United Kingdom, n = 117) of patients with previously untreated primary breast cancers. We report here that among the 13 human nuclear DNA polymerase genes, DNA Polymerase θ (POLQ) is the only one significantly up-regulated in breast cancer compared with normal breast tissues. Importantly, POLQ up-regulation significantly correlates with poor clinical outcome (4.3-fold increased risk of death in patients with high POLQ expression), and this correlation is independent of Cyclin E expression or the number of positive nodes, which are currently considered as markers for poor outcome. POLQ expression provides thus an additional indicator for the survival outcome of patients with high Cyclin E tumor expression or high number of positive lymph nodes. Furthermore, to decipher the molecular consequences of POLQ up-regulation in breast cancer, we generated human MRC5-SV cell lines that stably overexpress POLQ. Strong POLQ expression was directly associated with defective DNA replication fork progression and chromosomal damage. Therefore, POLQ overexpression may be a promising genetic instability and prognostic marker for breast cancer.
"Replicative stress" is one of the main factors underlying neoplasia from its early stages. Genes involved in DNA synthesis may therefore represent an underexplored source of potential prognostic markers for cancer. To this aim, we generated gene expression profiles from two independent cohorts (France, n = 206; United Kingdom, n = 117) of patients with previously untreated primary breast cancers. We report here that among the 13 human nuclear DNA polymerase genes, DNA Polymerase θ (POLQ) is the only one significantly up-regulated in breast cancer compared with normal breast tissues. Importantly, POLQ up-regulation significantly correlates with poor clinical outcome (4.3-fold increased risk of death in patients with high POLQ expression), and this correlation is independent of Cyclin E expression or the number of positive nodes, which are currently considered as markers for poor outcome. POLQ expression provides thus an additional indicator for the survival outcome of patients with high Cyclin E tumor expression or high number of positive lymph nodes. Furthermore, to decipher the molecular consequences of POLQ up-regulation in breast cancer, we generated human MRC5-SV cell lines that stably overexpress POLQ. Strong POLQ expression was directly associated with defective DNA replication fork progression and chromosomal damage. Therefore, POLQ overexpression may be a promising genetic instability and prognostic marker for breast cancer.
specialized DNA replication | prognosis marker | S-phase checkpoint B esides the "replicative" DNA polymerases POLA, POLD, and POLE, which are involved in conventional DNA replication of the undamaged genome, mammalian nuclei contain 10 additional specialized DNA polymerases that play a role in replication, repair, and recombination of damaged DNA (1, 2) and thus may be of paramount importance to preserve the integrity of the genome.
Specialized DNA polymerases are frequently deregulated in neoplasia (3) (4) (5) (6) (7) (8) (9) (10) . Indeed, the intracellular balance between the error-free, replicative polymerases POLA, POLD, and POLE and the error-prone, specialized DNA polymerases (POLH, POLL, POLM, POLN, POLK, POLB, POLI, POLQ, POLZ/REV3L, and REV1) appears to be of great importance for the maintenance of genome stability (11) (12) (13) (14) . Here, we wondered whether misregulation of DNA polymerases could be a signature of breast cancer progression. Indeed, beside the standard classification used by pathologists, there is a clear lack of tools to accurately predict the clinical outcome of many patients.
We specifically measured the expression levels of the 13 human replicative and specialized DNA polymerases in 206 breast carcinomas. We report that, differently from the replicative and the other specialized DNA polymerases, POLQ was significantly upregulated in most of the breast tumors analyzed. Such up-regulation was associated with poor clinical outcome.
POLQ is an error-prone, specialized DNA polymerase that might operate during "normal" genomic replication because it bypasses some endogenous DNA lesions and replicates undamaged DNA (15) (16) (17) . POLQ is also allelic to the murine chaos1 gene (for chromosome aberrations occurring spontaneously 1) (18) . The observation that chaos1 mutant mice display enhanced micronuclei in red blood cells further suggests a role of POLQ in maintaining genomic stability in the absence of any exogenous stress. In addition it seems to be involved in tolerance of bulky adducts or in DNA repair pathways such as the base-excision repair (BER), DNA interstrand cross-link (ICL), and DNA break repair pathways (19) (20) (21) (22) (23) . To investigate the molecular consequences of POLQ up-regulation, we generated human MRC5-SV cells that stably overexpressed the POLQ protein. We found that in such cells the elongation of the replication fork was slower than in control cells. Moreover, MRC5-SV cells that stably overexpress POLQ showed increased formation of γ-H2AX foci (the phosphorylated form of histone H2AX that accumulates in cells containing damaged DNA) and higher frequency of chromosomal abnormalities in comparison with control cells. These results suggest that POLQ overexpression, through the induction of genetic instability, could favor the emergence and survival of proliferating cancer cells.
Results POLQ is the most up-regulated DNA polymerase gene in breast tumors. To evaluate the gene expression profiles of both replicative (POLA, POLD, and POLE) and specialized (POLH, POLL, POLM, POLN, POLK, POLB, POLI, POLQ, POLZ/REV3L, and REV1) DNA polymerases in breast carcinoma, real-time PCR assays were performed by using a first set (n = 101; Table S1 ) of tumor (T) and nontumor (N) breast tissues from a French cohort of patients with breast carcinoma. The relative expression levels of the 13 DNA polymerases in each tumor were normalized to their median expression level in seven nontumor breast tissues (Fig. 1) . Among all of the polymerases analyzed, POLQ showed the highest T/N ratios. The expression of POLQ was 3-to 26-fold higher in tumor samples than in normal tissues. In 70 of the 101 tumors (69.3%) POLQ expression was up-regulated by 5-fold or more. Expression of POLN, which is the polymerase most closely related to POLQ (24), was also significantly higher in tumors. Very similar data were found when an independent analysis (i.e., using an independent batch of low-density arrays) was performed by using a second set of tumor samples from the cohort of French patients (n = 105; Table S1 and Fig. S1 ), with the exception of the POLB, REV1, POLI, and POLK T/N ratios, which were mostly <1 in this second group.
Then the nonparametric Spearman's correlation coefficients were calculated to assess the relationship between the expression data of the different polymerases. We found that in the first tumor set (n = 101), the expressions of the specialized polymerases POLN, POLM, POLK, POLL, and POLI were significantly correlated ( Fig. S2 ; all Spearman's correlation coefficients > 0.5). Conversely, the POLQ expression profile was not clustered in this pattern, indicating that POLQ up-regulation in tumors is independent from that of the other specialized polymerases.
Up-Regulation of POLQ in Breast Cancer Is Associated with Poor Clinical Outcome. To investigate whether the expression profile of the different DNA polymerases in breast tumors could be related to patients' survival, a log-rank test was carried out (Fig.  2) . For the French cohort, high expression of POLQ was significantly associated with poor survival (P = 0.0001) ( Fig. 2A) . This observation was supported by the results we obtained by using a second independent United Kingdom cohort of 117 patients with breast tumors (P = 0.035) (Table S1 , Fig. 2B ). Results for both French and United Kingdom cohorts were consistent, strongly supporting the association of POLQ upregulation with poorer survival in breast cancer patients.
Lymph node metastasis is also known to be associated with poor survival in breast cancer (25) . Results from both cohorts ( Fig. 2 C and D) indicated that patients with a high number of positive lymph nodes (i.e., nodes with metastatic breast cancer) had significantly poorer survival rate when POLQ also was upregulated (pairwise comparison, French cohort, P = 0.0001; British cohort, P = 0.002). Specifically, patients with high number of positive lymph nodes and low POLQ expression had a survival rate comparable with that of patients with low number of positive lymph nodes and high POLQ expression (pairwise comparison, French cohort, P = 0.793; British cohort, P = 0.882). Finally, patients with high number of positive lymph nodes and high POLQ expression showed very poor survival.
We then investigated the correlation between POLQ expression and the level of Cyclin E, a powerful predictor together with the number of positive lymph nodes of the outcome of breast cancer (refs. 25-27; Fig. S3A ). A Kaplan-Meier survival analysis (Fig.  S3A) indicated that the expression level of POLQ and Cyclin E constituted independent prognostic factors, even if up-regulation of POLQ was significantly more frequent in tumors that overexpressed Cyclin E (Spearman ρ = 0.71). To further confirm that POLQ and Cyclin E up-regulation are two independent cellular events, we depleted Cyclin E in MCF7 breast cancer cells, which overexpress Cyclin E, by RNA interference and could show that POLQ expression was not affected (Fig. S3 B) .
We then used a Cox proportional-hazards regression model to further examine the relationship between survival distribution and these different covariates. Univariate analysis confirmed that patients with tumors that strongly overexpressed POLQ had a 4.3-fold higher risk of death than patients with tumors that presented normal levels of POLQ (Table 1) . Moreover, multivariate analysis indicated that a close correlation between POLQ expression and survival still remained after adjusting the survival data by taking into account the expression of Cyclin E or the number of positive nodes (Table 1 ; P = 0.006, P = 0.04, and P = 0.006, P = 0.006, respectively).
Finally, a significant statistical association was found between POLQ expression and a number of prognostic indicators of breast cancer, such as histological grade III (P < 0.0001), tumor size (P = 0.0237), estrogen receptor (ER) status (P < 0.0001), progesterone receptor (PgR) status (P = 0.0034), Ki67 expression (P < 0.0001), HER2 status (P = 0.0032), and again the number of positive lymph nodes (P = 0.0172) (Table S2 ). Specifically, "triple-negative" Fig. 1 . Relative expression of replicative and specialized DNA polymerases in breast tumors from set 1 of the French cohort (n = 101). Normalized mRNA expression ratios for tumor (T) and normal (N) breast samples (T/N) were calculated. T/N > 1 and < 1 indicate higher and lower expression levels in tumors compared with pooled normal tissues, respectively. The individual T/N ratios were normalized to the expression of HMBS and IPO8, the two most stable control genes. T/N expression ratios were transformed into binomial data: 0 if T/N < 1; 1 if T/N > 1. The new variables then followed a binomial distribution according to the parameters n and p0, which represent the number of patients and the probability that a gene is overexpressed, respectively. To test the significance of a gene over-or underexpression, we checked if the p0 parameter of this binomial distribution was different from 0.5 by using bilateral exact binomial tests (null hypothesis: p0 = 0.5). Because of multiple testing, the P values from these tests were compared with a significance level obtained by using the Benjamini et al. procedure (39) for an overall false discovery rate (FDR) of 0.05. The patients' samples on the x axis are classified in the same order in each panel. + and -stand for higher and lower expression in the tumor (T) compared with the normal (N) tissues, respectively. For graph representation T/N values <1 were transformed into the inverse N/T values. tumors (i.e., ER negative, PgR negative, and HER2 negative) were more frequently associated with high levels of POLQ expression (P = 0.0422).
Ectopic Expression of POLQ Affects Cell Cycle and Proliferation. The previous data suggest that POLQ is either a bystander prognostic marker or that it might actively contribute to tumor progression. To differentiate between these two hypotheses, we decided to evaluate the specific impact of POLQ overexpression on genetic stability and cell proliferation. To this aim, we generated three clonal MRC5-SV cell lines (Q1, Q2, and Q3) that stably express increasing amounts of POLQ protein compared with the endogenous level displayed by the isogenic controls (Fig. S4A) . First, we examined the effect of POLQ overexpression on cell cycle progression. Quantitative FACS analysis after DNA staining by propidium iodide (Fig. S4B) revealed that MRC5-SV Q1, Q2, and especially Q3 (the cell line with the highest POLQ expression level) cells significantly accumulated in S phase compared with controls (cells transfected with the empty pcDNA 3.1 vector). MRC5-SV Q3 cells significantly accumulated in G 2 /M phase as well. To determine the length of the S phase, BrdU-pulsed MRC5-SV Q1 and Q3 cells were chased with thymidine, blocked at G 2 /M with nocodazole and collected at various times for FACS analysis (Fig. S5) . At 8 h, ≈25% of MRC5-SV Q1 and 31% Q3 cells were still in S-phase, whereas ≈89% of control cells had reached the G 2 /M phase, showing that excess POLQ affects the global duration of S phase. Collectively, these results indicate that up-regulation of POLQ in human cells affects cell cycle progression in the absence of external stress. Relationship between POLQ expression level to cancer-specific survival. In the French cohort, POLQ expression levels ≤0.063 were defined as "low expression." For the British cohort, POLQ expression ≤0.31 was defined as low expression. These cutoffs were defined in relation to survival to identify two statistically different populations of patients. ROC (Receiver Operating Characteristics) curves were used to determine the optimal cutoff point that best segregated patients in terms of survival. Cancer-specific survival was defined as the interval between the date of breast surgery and the date of death or of the last-follow-up (censored data). Patients who died from another cause were considered as censored observations. Survival rates were estimated according to the Kaplan-Meier method. (A and B) Kaplan-Meier survival curves of breast cancer patients according to the level of POLQ expression in the primary tumor. For these graphical representations, P values were given according to the log-rank test. A P value <0.05 was considered statistically significant. orescence assays to detect γ-H2AX, the phosphorylated form of histone H2AX that accumulates in cells containing damaged DNA. MRC5-SV Q1, Q2, and Q3 cells that overexpress POLQ showed a significant 2-to 3-fold increase in γ-H2AX foci formation compared with the isogenic controls ( Fig. 3 A and C). Immunoblotting analysis using anti-γ-H2AX antibodies ( Fig. S6A ) confirmed these data. We then determined the level of activation of CHK1 and CHK2, two central transducer kinases of the DNA damage response. Although the level of phosphorylated CHK1 did not differ between MRC5-SV Q1, Q2, and Q3 and control cells (Fig. S6B ), the number of phosphorylated CHK2 foci was significantly higher in MRC5-SV Q1, Q2, and Q3 cells (Q1, P < 0.0018; Q2, P < 0.002; Q3, P < 0.01) than in isogenic control cells (Fig. 3B ). Confocal analysis showed that, in Q1, Q2, and Q3 cells, most of the P T68 -CHK2 foci colocalized with the γ-H2AX foci (Fig. 3C ), indicating that activated CHK2 was localized to sites of DNA damage. Accumulation of γ-H2AX was directly linked to POLQ overexpression because siRNA-mediated depletion of POLQ in MRC5-SV Q3 fibroblasts (Fig. 3D ) and in MCF7 breast cancer cells (Fig. 3E ) significantly reduced the number of γ-H2AX-positive cells. This result suggests that overexpression of POLQ is associated with activation of the γ-H2AX-ATM-CHK2 DNA damage checkpoint.
POLQ Overexpressing Cells Display Spontaneous Chromosome
Abnormalities. To further investigate the consequences of POLQ overexpression on chromosomal stability, we analyzed metaphase spreads of MRC5-SV Q1, Q2, and Q3 cells and isogenic controls. POLQ overexpression was associated with a significant increase in the frequency of chromosomal abnormalities, mostly end-to-end fusions and chromatid breaks (Table S3 ). These data indicate that chromosome instability occurs in POLQ-overexpressing cells.
Replication Dynamics Is Perturbed in POLQ Overexpressing Cells. The previous results led us to examine replication dynamics in POLQ overexpressing cells. To assess whether POLQ overexpression affected the rate of replication fork progression, dynamic molecular combing was performed in MRC5-SV Q2 and Q3 as well as control cells. This method allowed us to determine the polarity of replication forks in vivo at the level of individual replicating DNA molecules and the distribution of fork velocities (Fig. 4) . The median speed was 1.699 kb/min in control MRC5-SV cells (empty pcDNA3 vector) (n = 144), 1.403 kb/min (n = 113) in Q2, and 1.402 kb/min (n = 200) in Q3 cells.
Because POLQ has been proposed to play a role in BER and translesion synthesis (TLS) (19, 21, 22, 25) , we hypothesized that overexpression of POLQ could interfere with the cellular tolerance to DNA damage (including damage generated by reactive oxygen species), thus leading to reduced kinetics of replication fork progression. Therefore, we measured the sensitivity of the POLQ overexpressing MRC5-SV cells to increasing doses of methylmethane-sulfonate (MMS) and N-Nitroso-N-Methylurea (MNU) (Fig. S7) , two agents known to induce DNA damage that is mostly repaired by BER. Survival of Q1, Q2, and Q3 cells was slightly affected upon MNU treatment and even less after incubation with MMS, suggesting that BER may be less effective or that bypass of unrepaired lesions is less effective in POLQ overexpressing cells. This result was confirmed by the analysis of two other POLQ overexpressing MRC5-SV clones (Q4 and Q5) in which POLQ expression was similar to that of Q3.
In conclusion, these data show that excess POLQ reduces DNA fork speed and induces DNA damage. Cell cycle progression abnormalities, genetic instability, and activation of the DNA damage checkpoint could then be consequences of defective DNA synthesis or tolerance to endogenous DNA damage in POLQ overexpressing cells.
Discussion
Our analysis of the gene expression profiles of untreated primary breast cancer samples from two independent cohorts of patients identify POLQ as the specialized DNA polymerase with the greatest change in expression in breast cancer compared with normal breast tissue. Our data differ from those of a previous study (6) , probably because we normalized all of the expression data to those of IPO8/HMBS, two genes which show very stable expression (Materials and Methods). Specifically, after normalization, breast tumor samples showed higher expression of the genes encoding the replicative DNA polymerases, and the T/N ratio for POLQ remained the highest in our analysis.
This result expands the range of human solid tumors in which up-regulation of POLQ has been reported (10) . The frequent upregulation of POLQ expression in a wide range of tumors suggests that this event is unlikely to be related to a particular carcinogen and may play a more general role favoring the survival and growth of unstressed, proliferating cells. We also show that POLQ up-regulation in breast cancer is independent from the expression of other specialized DNA polymerase genes. This data suggests that, in breast cancer, POLQ may be involved in a very specific pathway of DNA metabolism and that its upregulation might have a distinct physiological impact.
The most important finding we report here is that POLQ upregulation is significantly associated with poor clinical outcomes in two independent cohorts of patients suffering from breast cancer. To our knowledge, this is the first report in which the expression of a DNA polymerase is closely associated with the survival distribution of breast cancer patients. Statistical analysis of the two independent cohorts from two different countries show that among patients with metastatic lymph nodes, only the individuals with a high T/N ratio for POLQ expression had poor survival. Because the tumor, node, metastasis staging classification is a poor predictor of patients' survival, our results indicate that up-regulation of POLQ could be a useful prognostic factor to better forecast the potential outcome and to determine which patients merit more aggressive therapeutic measures. Furthermore, the correlation between high POLQ expression and the triple-negative phenotype (ER negative, PgR negative, HER2 negative phenotype, linked to the basal-like molecular subtype of breast cancer) supports the suggestion that genetic instability is an important feature of this specific subgroup of breast cancer with poorer prognosis (28) (29) . These data reveal that POLQ up-regulation is a unique and independent predictor of poor outcome in patients with breast cancer.
Our study also shows that overexpression of POLQ is associated with reduced DNA replication fork speed and induction of the DNA damage response as determined by phosphorylation of H2AX. The involvement of POLQ appears to be direct, because depletion of POLQ in MRC5-SV cells that overexpress POLQ or in MCF7 breast cancer cells reduces the γ-H2AX response.
These findings suggest that, in breast cancer, cells in which POLQ is up-regulated might be selected during early tumorigenesis, a stage in which the chronic activation of the replication and the DNA damage checkpoints has been shown to play a major role (30, 31) . Nevertheless, we cannot rule out the possibility that mechanisms other than DNA replication could be involved. Excess POLQ could titrate cofactors that are involved in TLS or DNA repair pathways, such as alternative nonhomologous end joining, ICL repair, or BER, where this polymerase might be involved (19) (20) (21) (22) (23) . Shorter DNA replication tracts and a modest sensitivity to alkylating agents in POLQ-overexpressing cells could therefore result from an accumulation of DNA damage due to these defective DNA transactions. Such deficiencies could lead to accumulation of single-strand gaps and, finally, to reduced kinetics of replication fork progression.
Cells expressing high amounts of POLQ also display gross cancerassociated chromosomal changes such as dicentric chromosomes or end-to-end fusions, which suggest a possible defect in telomere formation. The frequency of abnormal metaphases in POLQ overexpressing and chaos1 cells (32) are comparable, supporting the idea of the necessity of a tight regulation of POLQ expression.
Oncogene deregulation has been shown to modify the replicative program, thus inducing DNA damage during S phase and creating genetic instability in the absence of functional checkpoints (29) (30) (31) ). The present work shows also that unbalanced expression of DNA polymerases can mimic such an oncogenic effect by perturbing the course of replication forks and enhancing genetic instability. Further investigations are now required to better understand the role of POLQ deregulation in breast cancer and to define the best treatment for patients with cancers presenting POLQ gene upregulation, lymph node metastases, and/or Cyclin E overexpression to improve their survival rate. Indeed, inhibition of the expression/ activity of POLQ, a DNA repair protein, may increase responsiveness to conventional genotoxic treatments.
Materials and Methods
Study Design, Patient and Tumor Samples, Differential Gene Expression, and Statistical Analysis. A first cohort of tumor samples (n = 206) were obtained from is the sum of all DNA fibers that were studied for each clone; "n" is the number of tracks of IdU and CldU scored for each clone. The median value of the population is given in kilobases per min. The uncertainty of the median replication fork velocity is given in units of the median absolute deviation. The Mann-Whitney test was used to compare Q2 and Q3 data with the CTL2 control.
French patients with untreated (at the moment of the biopsy) primary breast cancer and who represented a subset of the women enrolled in an adjuvant multicentric phase III clinical trial (PACS01 trial). The characteristics of the patients and the results of this clinical trial have been published (33) . Tumor samples from this cohort were divided in two sets for gene expression analysis (n = 101 and n = 105). Normal breast tissues were obtained from the Claudius Regaud Institute (Toulouse, France) and taken from the surgical specimens, at more than 3 cm of distance from the breast cancer. A second cohort of tumor samples from randomly selected breast tumor patients (n = 117) was obtained from the Tayside Tissue Bank (Dundee, UK). The characteristics of the patients and tumors for both cohorts are described in Table S1 . Sample preparation and analysis of differential gene expression were as described (ref. 34 ; SI Materials and Methods). SI Materials and Methods also include the primer sequences and an extensive description of the statistical analyses.
Subcloning of POLQ. The design and construction of the POLQ-expression vector are described in SI Materials and Methods. To check the wild-type status of the exogenous POLQ, genomic DNA was extracted from the three MRC5-SV clones (Q1, Q2, and Q3) that stably overexpress POLQ, PCR-amplified and sequenced. The whole 7.7-kb cDNA sequence did not show any mutations (SI Materials and Methods). Genomic DNA was amplified by using primers that were complementary to different exons to prevent amplification of endogenous POLQ. POLQ DNA from CTL2 control cells was not amplified by using these primers, showing that the amplified sequences came from the transgene and not from endogenous POLQ DNA.
Cell Analysis and Transfections. MRC5-SV fibroblasts were transfected as described (35) . POLQ overexpression was immuno-detected as described (36), using purified, recombinant POLQ as size control. Cell cycle analysis and cytotoxicity studies were performed as reported (13) . To analyze S phase, cells were pulse-labeled with 10 μM BrdU for 15 min (Sigma-Aldrich), washed then incubated in 30 μM thymidine and 1 μM nocodazole (Sigma-Aldrich), collected, and fixed at various times in cold 70% ethanol. BrdU labeling and FACS analysis were then performed as described (35 On the other hand, for analyses of POLQ expression and patient survival in the French cohort, IPO8 was chosen as the normalizer. The calculated variances in set 1 (n = 101) and set 2 (n = 105) of the French cohort were the same (0.0033 for set 1 and 0.0031 for set 2, with a Student's t test P = 0.6510). In the British cohort, the expression level of POLQ was measured in triplicate in a multiplex reaction containing a set of primers and probes specific for POLQ ("TaqMan Gene Expression Assay", Applied Biosystems; assay ID Hs00198196_m1) and a set of primers and probes specific for TBP (TATA-box binding protein) as the normalizer gene. A calibrator sample (U2OS cDNA) was used in every plate. Probes and primers were assessed for their amplification efficiency by using serial dilutions of template DNA.
Cells. MRC5-SV human fibroblasts (HPA culture collection No. 84100401) and the MCF7 human breast adenocarcinoma cell line (ATCC HTB22) were grown in α-MEM media and RPMI medium 1640 containing 10% FCS, respectively (Invitrogen). Human mammary epithelial cells (HMEC) were a gift from J. Piette (Institut National de la Santé et de la Recherche Médicale, Montpellier, France).
Gene Silencing. Transfection of siRNA was carried out by using Lipofectamine 2000 (Invitrogen) and Luciferase (5′-CGUACGCGGAAUACUUCGAdTdT-3′), Cyclin E, or POLQ (both are specific ON-TARGET plus SMARTpool siRNAs; Dharmacon) siRNAs at a final concentration of 60 nM. The levels of POLQ and Cyclin E transcripts were measured by using the specific TaqMan Gene Expression Assays (Applied Biosystems) Hs00198196_m1 and Hs 00233356_m1, respectively. ΔCt values were normalized by using the Qbase software (http://medgen. ugent.be/qbase/) and the two HPRT (Hs01003267-m1) and YWHAZ (Hs00237047-m1) stable genes.
Statistical Analysis. Statistical analyses were performed by using the free statistical software R (version 2.9.2) including the "Survival" and "DiagnosisMed" packages (R development Team, http://cran. r-project.org) and the Stata software, version 10 (Stata). In the French cohort, the major parameters of analysis when comparing the expression of the different DNA polymerases in cancer and normal tissues were the individual T/N ratios normalized to the expression of the controls HMBS and IPO8. Conversely, in the analysis of POLQ or Cyclin E expression in relation to survival, the expression of genes was normalized to IPO8 only, and in the British cohort, ratios between POLQ expression (normalized to TBP) in each individual tumor and in U2OS cells were used. Correlations between genes were assessed with a nonparametric Spearman's correlation. Besides these analyses, the expression data were transformed into binomial data (i.e., more or less than 1) to use binomial exact tests to evaluate the significance of gene over-and underexpression defined as unbalanced groups ≈1. In the French cohort, POLQ and Cyclin E expression levels ≤0.063 and 0.182, respectively, were defined as "low expression." In the British cohort, POLQ gene expression ≤0.31 was defined as low expression. These cutoffs were defined in relation to survival to identify two statistically different populations of patients. ROC (Receiver Operating Characteristics) curves were used to determine which level (optimal cutoff point) of each gene expression best segregated patients in terms of survival. For both cohorts, a low number of metastatic lymph nodes was defined as a lymph node counts equal to 1 or less, distinct from patients with 2 or more metastatic axillary nodes. The cancer-specific survival was defined as the interval between the date of breast surgery and the date of death or of the last follow-up (censored data). Patients who died because of another cause were considered as censored observations. Survival rates were estimated according to the Kaplan-Meier method, and the log-rank test was used to assess the differences between groups. A Cox's proportional hazards regression model using a backward selection procedure and the likelihood ratio test was applied to investigate the impact of prognostic factors on cancer-specific survival. All variables associated with P < 0.05 on univariate analyses were included in the initial model. A χ 2 test was used to determine the existence of an association between two qualitative variables. All P values were two-sided. For all statistical tests, differences were considered significant at the 5% level.
Subcloning of POLQ. The human POLQ cDNA was cloned into the pcDNA 3.1/Hygro(+) vector (Invitrogen) (POLQ-pcDNA3.1) in two steps. First, the pFastBac-HTc POLQ plasmid that contains the POLQ ORF (2) was digested with RsrII and XhoI to obtain the N-terminal part of POLQ cDNA (1.2 kb). This product was inserted into pcDNA 3.1, previously digested with EcoRV and XhoI. The C-terminal part of POLQ cDNA (6.7 kb) was then isolated by digestion of the pFastBac-HTc POLQ plasmid with XhoI and SacII and inserted in the pcDNA 3.1/Hygro(+) vector that already contained the N-terminal part of POLQ cDNA after digestion with XhoI. The entire sequence of POLQ ORF was then confirmed by sequencing. Cells were propagated in medium containing 50 μg/mL hygromycin B.
POLQ ORF was also resequenced (by Millegen, France) after extraction of genomic DNA from MRC5-SV cells stably transfected with POLQ-pcDNA3.1 and amplification with the Pfu DNA polymerase (Promega) and the primers listed in the following table. Each couple of primers led to the replication of several exons to prevent amplification of the endogenous POLQ.
DNA Combing. In this method, replicated DNA is first consecutively labeled with two halogenated nucleosides, iododeoxyuridine (IdU) and chlorodeoxyuridine (CldU), for 20 min each, and then isolated and stretched as described (3) . Newly replicated regions ("replication tracks") in the stretched DNA molecules can then be visualized and measured by immunostaining with antibodies that are specific for CldU or IdU. PolQ1-S1  ATGAATCTTCTGCGTCGGAGTGGGA  1  PolQ1-R1  AGATACTCTCGCCTACTGTGTCCA  1480  PolQ2-S2  TGGACTCTGTATTACAGAAAACTGT  1202  PolQ2-R2  TAAGTCCTGCTGCAGAATCATTCT  2673  PolQ3-S3  TCAGAGAGCCAGGGTTCTCTAT  2412  PolQ3-R3  TCACTGGGTATCACAGTTCTGCT  3800  PolQ4-S4  TGACATCCATCCAATTAACCAGT  3561  PolQ4-R4  TTCTAGAGGACTGGATACTTTATCT  4962  PolQ5-S5  AAGTGATCCAGTACTTGATGAGCA  4779  PolQ5-R5  AAGCCAATTCCATTTAGTTCTA  6260  PolQ6-S6  AGCTTCCACTCCTAGAAGGGA  6047  PolQ6-R6  TTACACATCAAAGTCCTTTAGCTCT Tumors (n=105) Fig. S1 . Relative expression of replicative and specialized DNA polymerases in breast tumors from set 2 of the French cohort (n = 105). Normalized mRNA expression ratios for tumor (T) and normal (N) breast samples (T/N) were calculated. T/N > 1 and <1 indicate higher and lower expression levels in tumors compared with pooled normal tissues, respectively. The individual T/N ratios were normalized to the expression of the controls HMBS and IPO8, the two most stable control genes. T/N expression ratios were transformed into binomial data: 0 if T/N < 1; 1 if T/N > 1. The new variables then followed a binomial distribution according to the parameters n and p0, which represent the number of patients and the probability that a gene is overexpressed, respectively. To test the significance of a gene over-or underexpression, we checked whether the p0 parameter of this binomial distribution was different from 0.5 by using bilateral exact binomial tests (null hypothesis: p0 = 0.5). Because of multiple testing, the P values from these tests were compared with a significance level obtained using the Benjamini et al. (1) . Interplay between POLQ and Cyclin E. ROC (Receiver operating characteristics) curves were used to determine the expression level (optimal cutoff point) of each gene that best segregated patients in terms of survival. POLQ and Cyclin E expression level in tumors less than or equal to 0.063 and 0.182, respectively, was defined as low expression. Cancer-specific survival was defined as the interval between the date of breast surgery and the date of death or of the last followup (censored data). Patients who died due to another cause were considered as censored observations. Survival rates were estimated according to the Kaplan-Meier method, and the log-rank test was used to assess the differences between groups. (A) Kaplan-Meier survival of breast cancer patients from the French cohort, according to the expression levels of POLQ and Cyclin E in the primary tumor. We used a multivariate Cox model adjusted for POLQ and Cyclin E. The Spearman's correlation coefficient between POLQ and Cyclin E is indicated on the figure. (B) Western blots of whole-cell extracts of MCF7 breast cancer cells that were transfected with either control Luciferase (Luc) or Cyclin E siRNAs at 24 h after transfection. Normalized real-time PCR quantification of POLQ and Cyclin E expression in MCF7 breast cancer cells 24 h after transfection with control Luciferase or Cyclin E siRNAs (n = 3). At least three independent experiments were analyzed. The mean and SE were determined, and P values were calculated by using the Student's t test. ***P < 0.001; **P < 0.01. Cells were collected 3 h after colcemid treatment, and metaphase spreads were prepared. For quantification, a minimum of 100 metaphases were analyzed in three independent experiments. Results are the sums of four separate preparations of metaphases. P values were calculated by using the Student's t test.
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